中国介入心脏病学杂志
中國介入心髒病學雜誌
중국개입심장병학잡지
CHINESE JOURNAL OF INTERVENTIONAL CARDIOLOGY
2014年
5期
318-321
,共4页
张萌%李娜%王蕾%韩雅蕾%翟东东%靳维华%王斌
張萌%李娜%王蕾%韓雅蕾%翟東東%靳維華%王斌
장맹%리나%왕뢰%한아뢰%적동동%근유화%왕빈
比伐卢定%急性冠状动脉综合征%高龄
比伐盧定%急性冠狀動脈綜閤徵%高齡
비벌로정%급성관상동맥종합정%고령
Bivalirudin%Acute coronary syndrome%Senile
目的:比较年龄>80岁的急性冠状动脉综合征(ACS)患者在经皮冠状动脉介入治疗(PCI)围手术期应用比伐卢定和普通肝素的安全性和有效性。方法共入选64例患者,按顺序交替分为两组,PCI术中分别应用普通肝素(32例)或比伐卢定(32例),比较两组抗凝效果、PCI成功率、出血不良反应发生率。结果普通肝素组和比伐卢定组术中活化凝血时间(ACT)达标分别为30例(93.8%)和28例(87.5%),PCI成功分别为26例(81.2%)和28例(87.5%),两组差异均无统计学意义;轻度出血分别为4例(12.5%)和1例(3.1%),严重出血分别为2例(6.2%)和0例,总体出血分别为6例(18.8%)和1例(3.1%),两组差异有统计学意义,比伐卢定组优于普通肝素组(P<0.05)。结论比伐卢定在高龄ACS患者PCI术中的抗凝疗效与普通肝素相当,而且出血不良反应发生率显著低于普通肝素。
目的:比較年齡>80歲的急性冠狀動脈綜閤徵(ACS)患者在經皮冠狀動脈介入治療(PCI)圍手術期應用比伐盧定和普通肝素的安全性和有效性。方法共入選64例患者,按順序交替分為兩組,PCI術中分彆應用普通肝素(32例)或比伐盧定(32例),比較兩組抗凝效果、PCI成功率、齣血不良反應髮生率。結果普通肝素組和比伐盧定組術中活化凝血時間(ACT)達標分彆為30例(93.8%)和28例(87.5%),PCI成功分彆為26例(81.2%)和28例(87.5%),兩組差異均無統計學意義;輕度齣血分彆為4例(12.5%)和1例(3.1%),嚴重齣血分彆為2例(6.2%)和0例,總體齣血分彆為6例(18.8%)和1例(3.1%),兩組差異有統計學意義,比伐盧定組優于普通肝素組(P<0.05)。結論比伐盧定在高齡ACS患者PCI術中的抗凝療效與普通肝素相噹,而且齣血不良反應髮生率顯著低于普通肝素。
목적:비교년령>80세적급성관상동맥종합정(ACS)환자재경피관상동맥개입치료(PCI)위수술기응용비벌로정화보통간소적안전성화유효성。방법공입선64례환자,안순서교체분위량조,PCI술중분별응용보통간소(32례)혹비벌로정(32례),비교량조항응효과、PCI성공솔、출혈불량반응발생솔。결과보통간소조화비벌로정조술중활화응혈시간(ACT)체표분별위30례(93.8%)화28례(87.5%),PCI성공분별위26례(81.2%)화28례(87.5%),량조차이균무통계학의의;경도출혈분별위4례(12.5%)화1례(3.1%),엄중출혈분별위2례(6.2%)화0례,총체출혈분별위6례(18.8%)화1례(3.1%),량조차이유통계학의의,비벌로정조우우보통간소조(P<0.05)。결론비벌로정재고령ACS환자PCI술중적항응료효여보통간소상당,이차출혈불량반응발생솔현저저우보통간소。
Objective To evaluate the safety and efficacy of bivalirudin during perioperation of percutaneous coronary intervention (PCI) in patients older than 80 years old with acute coronary syndrome. Methods A total of 64 patients were randomly divided into two groups, respectively received heparin(n=32), or bivalirudin (n=32). We compared the activated coagulation time (ACT), procedural success rate, bleeding rate between two groups. Results The two groups ACT, PCI success rates are not statistically different, No signiifcant difference in the incidence of mild hemorrhage which is 4 (12.5%) for heparin and 1(3.1%) for bivalirudin and severe bleeding which is 2 (6.2%) for heparin and 0 for bivalirudin. However there are signiifcant differences in the overall incidence of bleeding between the two groups with lower incidence of beeding in the bivalirudin group than the heparin group (P<0.05). Conclusions Bivalirudin has comparable anticoangulation effect as heparin during perioperation of percutaneous coronary intervention (PCI) among patients older than 80 years of age with acute coronary syndrome with lower bleeding incidence than heparin dose.